Grifols Therapeutics Inc. – FDA 483, Mar 18, 2014

The provided document is an FDA Form 483, a report issued by the Food and Drug Administration to inform a company of objectionable conditions or practices observed during an inspection. However, the specific details regarding the company name, the precise inspection dates, and the core violations or issues identified are not available in the provided text due to extensive redactions, indicated by '(b) (4)'. The regulatory framework for this document is clearly stated as Section 704(b) of the Federal Food, Drug, and Cosmetic Act. This section outlines the inspector's duty to report any conditions or practices that suggest a food, drug, device, or cosmetic may be adulterated or has been prepared, packed, or held under insanitary conditions, potentially rendering it injurious to health. The form serves to assist inspected firms in understanding and complying with the Acts and regulations enforced by the FDA. Without the unredacted content, it is impossible to detail the specific required actions for the inspected entity, as these actions would directly stem from the observed violations. Consequently, a comprehensive summary including all requested elements such as specific findings and company-specific actions cannot be fully generated from this redacted information.